CGF +0.78%: Released FY21 earnings this morning that were smack on expectations, both in terms of earnings for FY21 and guidance for FY22. Normalised pre-tax profit of $396m for FY21 will jump by ~15% over the coming 12 months if they meet the midpoint of stated guidance (pre-tax profit $430m-$480m) as continued strength in annuity sales (sales doubled in 2H21 to $2.4bn) underpin the ongoing turnaround in the business. Higher interest rates would help as would an uptick in funds management fees. CGF have had a difficult time through COVID having cut risk in their book at the lows, battling an extended period of super low interest rates plus now they’ve also lost another CEO just 2.5 years into a 5 year term, however there is value there trading on ~14x earnings that are growing, just a few warts as well!
scroll
Question asked
Question asked
Question asked
Performance update for March, stocks that drove returns & our current positioning
Close
Thursday 18th April – ASX200 +32pts, Resmed (RMD), Transurban (TCL), Santos (STO) & SRG Global (SRG)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
Thursday 18th April – DOW -45pts, SPI +20pts
Close
MM is neutral CGF, seeing some value around $5.86
Add To Hit List
Related Q&A
Picking a healthcare winner
Technical thoughts on CGF & HLS
Our view of Challenger (CGF)
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Thursday 18th April – ASX200 +32pts, Resmed (RMD), Transurban (TCL), Santos (STO) & SRG Global (SRG)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Podcast
LISTEN
Thursday 18th April – DOW -45pts, SPI +20pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.